Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study

Table 3 Univariate and multivariate analysis of covariables associated with overall survival from the start of second-line chemotherapy

Variables	Univariate	p-value	Multivariate	p-value
	HR		HR
	(95% CI)		(95% CI)
Second-line chemotherapy
Platinum-doublet vs Single agent	0.54	< 0.01	0.53	< 0.01
Platinum-doublet vs Single agent	(0.40 to 0.73)		(0.39 to 0.73)
Age
≥ 75 years vs < 75 years	0.79	0.41	0.82	0.51
≥ 75 years vs < 75 years	(0.45 to 1.34)		(0.45 to 1.49)
Sex
Female vs Male	0.57	0.02	0.55	0.01
Female vs Male	(0.36 to 0.91)		(0.34 to 0.88)
ECOG PS
0/1 vs 2	2.15	0.28	2.59	0.19
0/1 vs 2	(0.53 to 8.65)		(0.63 to 10.6)
Smoking status
Never or former smoker vs Current smoker	0.84	0.23	0.94	0.70
Never or former smoker vs Current smoker	(0.63 to 1.12)		(0.70 to 1.27)
Histology
Adenocarcinoma vs Non-adenocarcinoma	0.98	0.87	1.14	0.38
Adenocarcinoma vs Non-adenocarcinoma	(0.73 to 1.30)		(0.85 to 1.54)
Clinical stage
IIIA vs IIIB	0.62	< 0.01	0.67	< 0.01
IIIA vs IIIB	(0.47 to 0.82)		(0.50 to 0.90)
Respiratory comorbidity
No vs Yes	0.95	0.95	0.95	0.75
No vs Yes	(0.71 to 1.27)		(0.70 to 1.29)
Response to first-line chemoradiotherapy
CR or PR vs not CR nor PR	0.94	0.71	0.94	0.72
CR or PR vs not CR nor PR	(0.70 to 1.28)		(0.68 to 1.30)
Duration from the start of first-line therapy to second-line therapy
≥ 8.6 months vs < 8.6 months	0.82	0.16	0.74	0.048
≥ 8.6 months vs < 8.6 months	(0.62 to 1.08)		(0.55 to 0.997)

CI confidence interval, CR complete response, ECOG PS Eastern Cooperative Oncology Group performance status, HR hazard ratio, PR partial response

ISSN: 1471-2407